IR Side Nav
BioNTech to Report Third Quarter 2020 Financial Results and Operational Update on November 10, 2020
Mainz, Germany, November 3, 2020 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2020 on Tuesday, November 10th, 2020. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 08:00 a.m. EDT (2:00 p.m. CET) to report its financial results and provide a corporate update on the third quarter 2020.
The slide presentation and audio of the webcast will be available via the following link: https://edge.media-server.com/mmc/p/jqhpczzu
To participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID:
|United States international:||+1 646 741 3167|
|United States domestic (toll-free):||+1 877 870 9135|
|Germany:||+49 (0) 692 2222 625|
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at https://biontech.de/. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
For more information, please visit www.BioNTech.de.
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
+49 (0)6131 9084 1513 or +49 (0)151 1978 1385